Research
Hormonal
Incretin-based therapies resulted in significant reductions in body weight and/or body mass index in patients with obstructive sleep apnea.
Practitioners may consider incretin-based therapies as effective options for weight management in OSA patients.
StrongSupportsmedium confidence
Collectively, the studies enrolled 1024 patients, lasted ≥12 weeks with liraglutide or tirzepatide, and resulted in significant reductions in body weight and/or body mass index.
Why this rating
Based on the systematic review and meta-analysis of randomized controlled trials.
Source
Efficacy of incretin-based therapies in obesity-related obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials
Anna Bardóczi et al. · Sleep Medicine Reviews · 2025
DOI 10.1016/j.smrv.2025.102119
Meta-analysisCited 12×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →